TNXP Stock Soars After Announcing License Deal for TNX-1700

TNXP stock

Positive news with regards to a cancer medicine almost always sends the stock of a pharmaceutical company higher, and that is what happened with TNXP stock in Tuesday’s trading session.

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) announced that its product TNX-1700, which is meant for the treatment of pancreatic and gastric cancers, has managed to acquire an in-licensing deal with the venerated Columbia University. It goes without saying that it is a significant development and the market thought so as well.

Key Deal

The medicine in question is being referred to as a recombinant trefoil ...

Read The Full Article On MicroSmallCap.com

Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.

All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.